Total Payments
$211,376
2024 Payments
$26,372
Companies
37
Transactions
382
Medicare Patients
7,520
Medicare Billing
$5.3M
Payment Breakdown by Category
Consulting$103,694 (49.1%)
Other$63,024 (29.8%)
Food & Beverage$16,198 (7.7%)
Travel$14,307 (6.8%)
Research$14,153 (6.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $103,694 | 39 | 49.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $51,732 | 13 | 24.5% |
| Food and Beverage | $16,198 | 261 | 7.7% |
| Travel and Lodging | $14,307 | 39 | 6.8% |
| Unspecified | $14,153 | 22 | 6.7% |
| Current or prospective ownership or investment interest | $9,283 | 5 | 4.4% |
| Honoraria | $2,009 | 3 | 1.0% |
Payments by Type
General
$197,222
360 transactions
Research
$14,153
16 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $63,673 | 87 | $0 (2024) |
| Genentech, Inc. | $39,282 | 34 | $0 (2022) |
| F. Hoffmann-La Roche AG | $15,895 | 15 | $0 (2024) |
| Coherus Biosciences Inc. | $14,436 | 10 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $12,698 | 18 | $0 (2023) |
| Ocular Therapeutix, Inc. | $10,963 | 11 | $0 (2024) |
| Alcon Research LLC | $10,187 | 3 | $0 (2021) |
| US Retina LLC | $9,283 | 11 | $0 (2022) |
| Allergan, Inc. | $8,339 | 24 | $0 (2021) |
| Amgen Inc. | $6,264 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,372 | 60 | F. Hoffmann-La Roche AG ($12,548) |
| 2023 | $36,011 | 65 | Genentech USA, Inc. ($25,895) |
| 2022 | $69,465 | 75 | Genentech USA, Inc. ($19,848) |
| 2021 | $18,062 | 21 | Alcon Research LLC ($10,187) |
| 2020 | $10,712 | 22 | Ocular Therapeutix, Inc. ($5,100) |
| 2019 | $20,127 | 45 | Genentech, Inc. ($7,145) |
| 2018 | $10,502 | 42 | Genentech, Inc. ($6,518) |
| 2017 | $20,125 | 52 | Genentech, Inc. ($11,495) |
All Payment Transactions
382 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $100.87 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $33.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | Cash or cash equivalent | $29.68 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/06/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,720.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/06/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,520.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/05/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $34.89 | General |
| Category: Ophthalmology | ||||||
| 11/20/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $5.56 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/14/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | In-kind items and services | $791.95 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/14/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | In-kind items and services | $325.63 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/14/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $117.10 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/13/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $31.85 | General |
| Category: EYE CARE | ||||||
| 11/08/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $42.25 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $30.19 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/05/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | In-kind items and services | $60.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/23/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $26.19 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/20/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $27.18 | General |
| Category: EYE CARE | ||||||
| 10/19/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $32.63 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,814.00 | Research |
| Study: VA2 PhIII | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,272.73 | Research |
| Study: Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-related Macular Degeneration or Diabetic Macular Edema | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $954.29 | Research |
| Study: VA2 PhIII | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $685.13 | Research |
| Study: VA2 PhIII | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $533.33 | Research |
| Study: VA2 PhIII | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $477.14 | Research |
| Study: VA2 PhIII | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $240.71 | Research |
| Study: VA2 PhIII | ||||||
| 09/18/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $30.40 | General |
| Category: EYE CARE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| VA2 PhIII | F. Hoffmann-La Roche AG | $6,722 | 10 |
| Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-related Macular Degeneration or Diabetic Macular Edema | F. Hoffmann-La Roche AG | $4,509 | 2 |
| Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for up to 16 Weeks in Neovascular Age-related Macular Degeneration and Diabetic Macular Edema | F. Hoffmann-La Roche AG | $2,497 | 2 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $425.50 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,469 | 4,865 | $1.7M | $591,706 |
| 2022 | 6 | 861 | 1,186 | $164,865 | $72,385 |
| 2021 | 4 | 383 | 408 | $55,540 | $26,736 |
| 2020 | 17 | 4,807 | 24,550 | $10.8M | $4.6M |
Total Patients
7,520
Total Services
31,009
Medicare Billing
$5.3M
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3490 | Unclassified drugs | Office | 2023 | 32 | 116 | $489,000 | $197,758 | 40.4% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 42 | 552 | $441,680 | $120,569 | 27.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 22 | 110 | $137,500 | $75,522 | 54.9% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 13 | 2,100 | $147,000 | $60,614 | 41.2% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 301 | 408 | $71,400 | $41,631 | 58.3% |
| 67028 | Injection of drug into eye | Office | 2023 | 103 | 300 | $283,500 | $32,921 | 11.6% |
| 92134 | Imaging of retina | Office | 2023 | 279 | 498 | $62,250 | $17,075 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 129 | 132 | $22,440 | $10,955 | 48.8% |
| 92250 | Photography of the retina | Office | 2023 | 296 | 342 | $32,490 | $9,941 | 30.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 61 | 106 | $13,250 | $8,413 | 63.5% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 49 | 51 | $8,925 | $6,361 | 71.3% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 40 | 40 | $8,040 | $4,879 | 60.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $6,160 | $3,480 | 56.5% |
| 92133 | Imaging of optic nerve | Office | 2023 | 21 | 24 | $3,000 | $676.86 | 22.6% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 33 | 37 | $7,400 | $489.01 | 6.6% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 20 | 21 | $4,200 | $419.82 | 10.0% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 314 | 481 | $84,175 | $45,769 | 54.4% |
| 92250 | Photography of the retina | Office | 2022 | 290 | 385 | $36,575 | $11,310 | 30.9% |
| 92134 | Imaging of retina | Office | 2022 | 193 | 256 | $32,000 | $7,824 | 24.5% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 33 | 33 | $5,775 | $3,567 | 61.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $4,180 | $2,450 | 58.6% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 12 | 12 | $2,160 | $1,465 | 67.8% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 144 | 154 | $26,950 | $16,883 | 62.6% |
| 92250 | Photography of the retina | Office | 2021 | 122 | 127 | $12,065 | $4,413 | 36.6% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 105 | 114 | $14,250 | $4,026 | 28.3% |
About Dr. Robert Avery, M.D
Dr. Robert Avery, M.D is a Retina Specialist healthcare provider based in Santa Barbara, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700985496.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Avery, M.D has received a total of $211,376 in payments from pharmaceutical and medical device companies, with $26,372 received in 2024. These payments were reported across 382 transactions from 37 companies. The most common payment nature is "Consulting Fee" ($103,694).
As a Medicare-enrolled provider, Avery has provided services to 7,520 Medicare beneficiaries, totaling 31,009 services with total Medicare billing of $5.3M. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Specialist
- Location Santa Barbara, CA
- Active Since 09/21/2006
- Last Updated 06/06/2022
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1700985496
Products in Payments
- Vabysmo (Drug) $29,590
- VABYSMO (Drug) $24,658
- Lucentis (Biological) $22,818
- Cimerli (Biological) $14,436
- XIPERE (Drug) $12,195
- Non-Covered Product (Drug) $11,553
- DEXTENZA (Drug) $5,613
- OZURDEX (Drug) $4,830
- TYRVAYA (Drug) $2,142
- VISUDYNE (Drug) $1,703
- EYLEA AFLIBERCEPT INJECTION (Biological) $1,516
- EYP-1901 (Drug) $1,440
- EYLEA (Biological) $1,431
- Syfovre (Drug) $436.78
- EYLEA HD (Biological) $401.66
- YUTIQ (Drug) $381.52
- Constellation (Device) $318.77
- OMNI (Device) $239.80
- Iluvien (Biological) $172.58
- DEXYCU (Drug) $165.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.